Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Jul-Sep;43(3):269-274.
doi: 10.12865/CHSJ.43.03.15. Epub 2017 Sep 28.

Therapeutic Options in Diffuse Large B-Cell Lymphoma - A Retrospective Study and Review of the Literature

Ana-Maria Patrascu  1 , Janina Nacea  1 , Ş Patrascu  2 , A Goganau  2 , Florentina Delcea  3 , L Mogoanta  4 , Ionela Rotaru  1
Affiliations
Case Reports

Therapeutic Options in Diffuse Large B-Cell Lymphoma - A Retrospective Study and Review of the Literature

Ana-Maria Patrascu et al. Curr Health Sci J. 2017 Jul-Sep.

Abstract

The aim of this retrospective study was to assess the differences between standard R-CHOP and other Rituximab-associated chemotherapy (R-miniCHOP and R-CHOEP) regimens in terms of survival and potential adverse effects. The six-month survival outcomes of 94 diffuse large B-cell lymphomas (DLBCL) patients indicated no statistical difference between overall survival and disease-free survival in the two subgroups. The biological response to therapy (blood count, LDH levels) was similar in both subgroups. Despite having different clinical indications, R-miniCHOP and R-CHOEP provide viable therapeutic alternatives to the standard R-CHOP regimen.

Keywords: CHOP; diffuse large B-cell lymphoma; prognosis; rituximab.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Patients distribution according to DLBCL treatment regimen
Figure 2
Figure 2
Overall survival for R-CHOP vs. alternative Rituximab-based regimens in DLBCL patients
Figure 3
Figure 3
Disease-free survival for R-CHOP vs. alternative Rituximab-based regimens in DLBCL patients
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Carbone A, Gloghini A, Kwong YL, Younes A. Diffuse large B cell Lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy. Ann Hematol. 2014;93:1263–1277. - PMC - PubMed
    1. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235–242. - PubMed
    1. Gang AO, Strøm C, Pedersen M, d'Amore F, Pedersen LM, Bukh A, Pedersen BB, Moeller MB, Mortensen LS, Gadeberg OV, Ingeberg S, Mourits-Andersen T, Pulczynski S, d Nully Brown P. R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group. Ann Oncol. 2012;23(1):147–153. - PubMed
    1. Wästerlid T, Szekely E, Werner Hartman L, Jerkeman M. R-CHOEP-14 is associated with superior overall survival compared to R-CHOP-21 and R-CHOP-14 in patients with DLBCL ≤70 Years-a Swedish lymphoma registry population based study. Blood. 2014;124(21):4427–4427.
    1. Peyrade F, Jardin F, Thieblemont C, Thyss A, Emile JF, Castaigne S, Coiffier B, Haioun C, Bologna S, Fitoussi O, Lepeu G, Fruchart C, Bordessoule D, Blanc M, Delarue R, Janvier M, Salles B, André M, Fournier M, Gaulard P, Tilly H; Groupe d'Etude des Lymphomes de l'Adulte (GELA) investigators. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2011;12(5):460–468. - PubMed

Publication types

LinkOut - more resources